Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solvonis TherapeuticsFRA:J4I -25.00% EBIT per Share is €-0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 2,499 Industrial Products companies, Solvonis Therapeutics ranks better than 93.96% on this metric.
Solvonis Therapeutics's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 66.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 27.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Solvonis Therapeutics's EBIT per Share or its related term are showing as below:
FRA:J4I'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -73.8 Med: 0 Max: 66.2
Current: 66.2
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Solvonis Therapeutics was 66.20% per year. The lowest was -73.80% per year. And the median was 0.00% per year.
FRA:J4I's 3-Year EBIT Growth Rate is ranked better than 93.96% of 2499
companies
in the Industrial Products industry
Industry Median: 4.8
vs FRA:J4I: 66.20
Solvonis Therapeutics (FRA:J4I) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Solvonis Therapeutics EBIT per Share Related Terms
Solvonis Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Solvonis Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solvonis Therapeutics (FRA:J4I) has a EBIT per Share of €-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #151 out of 2499 companies in the Industrial Products industry, placing it in the top 6%.
Is Solvonis Therapeutics' EBIT per Share too high?
Solvonis Therapeutics' current EBIT per Share is €-0.00. Based on the distribution chart, Solvonis Therapeutics ranks #151 out of 2499 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers.
How does Solvonis Therapeutics' EBIT per Share compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #151 out of 2499 companies for EBIT per Share. This places Solvonis Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 4.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Industrial Products company?
The median EBIT per Share among Industrial Products companies is 4.80, based on 2,499 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median EBIT per Share is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (FRA:J4I) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 85% below its estimated fair value. The current EBIT per Share is €-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Solvonis Therapeutics (FRA:J4I), the current EBIT per Share is €-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J4I has been successfully added to your 
